


Oncology
2024-06-15

Antibody-drug conjugates (ADCs) are promising cancer treatments that include delivering toxic drugs to specific tumor cells. Xenograft tumor models based on immunodeficient mice are suitable for evaluating the anti-tumor effect of ADCs. Tumor models of immunocompetent animals may be more suitable when evaluating antibody-mediated immune response of ADCs and the combined effect of ADCs and immunotherapy. Aiming at this issue, we developed humanized mouse models to evaluate the efficacy of ADCs in combination with immunotherapy.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
